Paralos Bioscience Inc.

Paralos Bioscience Inc. is a biotechnology company developing a first-in-class phage-drug conjugate delivery platform. The company utilizes engineered M13 bacteriophage to separate drug targeting from payload loading, allowing for the precise tuning of drug delivery. Their technology platform is designed to provide high drug loading, programmable binding to bacterial targets, and a repeatable manufacturing process in E. coli. Additionally, the company operates as a contract research organization (CRO) providing custom phage display services, including M13 constructs and libraries for research applications.

This platform enables a plug-and-play strategy for developing targeted therapies, with an initial focus on addressing high-value hospital infections and drug-resistant pathogens. By converting proven drugs into differentiated targeted therapies, Paralos aims to expand its pipeline across various indications and pathogens. The company's approach is intended to solve challenges in drug delivery by enabling the customization of targeting ligands and payloads, providing partners and researchers with scalable tools for therapeutic development and specialized biological research.